Cetera Investment Advisers Bei Gene, Ltd. Transaction History
Cetera Investment Advisers
- $49.2 Billion
- Q1 2025
A detailed history of Cetera Investment Advisers transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Cetera Investment Advisers holds 1,772 shares of BGNE stock, worth $401,730. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,772
Previous 1,891
6.29%
Holding current value
$401,730
Previous $349,000
14.9%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding BGNE
# of Institutions
295Shares Held
40.1MCall Options Held
111KPut Options Held
114K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion23.78% of portfolio
-
Capital International Investors Los Angeles, CA5.09MShares$1.15 Billion0.24% of portfolio
-
Primecap Management CO Pasadena, CA5.06MShares$1.15 Billion0.97% of portfolio
-
Baillie Gifford & CO3.63MShares$823 Million0.74% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.71MShares$615 Million0.09% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...